CTLA4 and neoplasm: Nowadays, advancements in immune checkpoint inhibitors (ICIs) therapy (anti-CTLA-4 and anti-PD-1 monoclonal antibodies) have reduced tumor recurrence rates and, therefore, improved OS in patients with ARM [16-18].